Janssen reports long-term safety data for esketamine in treatment-resistant depression

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported data from the Phase III SUSTAIN-2 long-term safety study evaluating intranasal esketamine (formerly JNJ-54135419)

Read the full 250 word article

User Sign In